Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 21 (37), 10604-8

Sub-classification of Intermediate-Stage (Barcelona Clinic Liver Cancer stage-B) Hepatocellular Carcinomas

Affiliations
Review

Sub-classification of Intermediate-Stage (Barcelona Clinic Liver Cancer stage-B) Hepatocellular Carcinomas

Koichiro Yamakado et al. World J Gastroenterol.

Abstract

Hepatocellular carcinoma (HCC), the fifth most common cancer in the world, shows increasing incidence worldwide. Curative treatments such as hepatectomy, liver transplantation, and radiofrequency ablation are applied in only 30%-60% of cases. Most remaining patients receive transarterial chemoembolization (TACE). Patients with intermediate-stage HCCs are regarded as good candidates for TACE. However, the intermediate stage includes non-homogeneous patients. Some movements are underway to stratify patients using prognostic factors to identify patient groups exhibiting greater benefit from TACE than other patient groups. This review describes two substaging systems that subclassify intermediate-stage HCCs and discusses the importance of dividing intermediate-stage patients.

Keywords: Chemoembolization; Child-Pugh score; Hepatocellular carcinoma; Intermediate-stage; Prognosis.

Similar articles

See all similar articles

Cited by 4 PubMed Central articles

Feedback